Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 14, 2021 08:30 ET | Source: I-Mab

I-Mab Announces Selected Poster Presentation of CD73 Antibody Uliledlimab at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

SHANGHAI, China., and GAITHERSBURG, MD, April 14, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development...
April 06, 2021 08:00 ET | Source: I-Mab

I-Mab and ABL Bio Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody TJ-L14B/ABL503 in Patients with Advanced or Metastatic Solid Tumors

SHANGHAI, China and GAITHERSBURG, Md. and SEONGNAM, South Korea, April 06, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the...
March 31, 2021 08:00 ET | Source: I-Mab

I-Mab Announces Upcoming Participation at April Conferences

SHANGHAI, China and GAITHERSBURG, Md., March 31, 2021 (GLOBE NEWSWIRE) -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and...
March 30, 2021 08:00 ET | Source: I-Mab

I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors

SHANGHAI, China and GAITHERSBURG, Md., March 30, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the development of novel...
March 29, 2021 07:00 ET | Source: I-Mab

I-Mab Reports Financial Results for Full Year of 2020 and Provides Business Updates

18 significant clinical milestones achieved since the Company’s IPO in January 2020, with multiple important data readouts for lemzoparlimab (TJC4), uliledlimab (TJD5) and other clinical assets...
March 24, 2021 08:00 ET | Source: I-Mab

I-Mab to Host 2021 R&D Day

Mandarin session on April 7, 2021 and English session on April 26, 2021 for investors and research analysts SHANGHAI, China and GAITHERSBURG, Md., March 24, 2021 (GLOBE NEWSWIRE) -- I-Mab (the...
March 19, 2021 16:20 ET | Source: I-Mab

I-Mab Files Prospectus Supplement for Shelf Registration for Hillhouse

SHANGHAI, China and GAITHERSBURG, Md., March 19, 2021 (GLOBE NEWSWIRE) -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and...
March 11, 2021 08:00 ET | Source: I-Mab

I-Mab To Present Differentiated Mechanism of Action and Preclinical Data for Anti-CD73 Antibody Uliledlimab at 2021 American Association for Cancer Research Annual Meeting

SHANGHAI, China and GAITHERSBURG, Md., March 11, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and...
March 10, 2021 08:00 ET | Source: I-Mab

I-Mab Launches Discovery Initiative to Expand Transformational Immuno-Oncology Pipeline

- New Initiative is part of I-Mab’s long-term strategy to drive innovation and scientific leadership in immuno-oncology- New collaborations signed will allow I-Mab access to cutting edge technology...
April 29, 2020 09:24 ET | Source: I-Mab

I-Mab Filed 2019 Annual Report on Form 20-F

SHANGHAI, China and ROCKVILLE, MD., April 29, 2020 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and...

Next Page keyboard_arrow_right